Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.
Identifieur interne : 001787 ( PubMed/Corpus ); précédent : 001786; suivant : 001788Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.
Auteurs : U. Sabatini ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J P Marc-Vergnes ; J L MontastrucSource :
- British journal of clinical pharmacology [ 0306-5251 ] ; 1991.
English descriptors
- KwdEn :
- Aged, Apomorphine (administration & dosage), Apomorphine (pharmacology), Blood Pressure (drug effects), Cerebrovascular Circulation (drug effects), Domperidone (pharmacology), Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Parkinson Disease (physiopathology), Psychomotor Performance (drug effects), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , administration & dosage : Apomorphine.
- chemical , pharmacology : Apomorphine, Domperidone.
- drug effects : Blood Pressure, Cerebrovascular Circulation, Psychomotor Performance.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Tomography, Emission-Computed, Single-Photon.
Abstract
1. We have measured regional cerebral blood flow (rCBF) and motor function before and after the subcutaneous (s.c.) injection of apomorphine in parkinsonian patients deprived of their usual treatment for at least 48 h. 2. Nineteen patients, pretreated with domperidone (20 mg three times daily for 48 h), received a mean dose of 5.8 mg s.c. apomorphine. All patients switched 'on'. The mean motor score was significantly improved (-65%, P less than 0.01) but no significant change in rCBF was observed. 3. Seven other patients, not pretreated with domperidone, received a lower dose (0.3 mg) of s.c. apomorphine. No change in motor score was observed while the mean rCBF significantly increased (+12%, P less than 0.05). 4. We conclude that s.c. apomorphine increases rCBF in parkinsonian patients. This effect is independent of the central therapeutic effects of the drug. It is mediated by the stimulation of dopaminergic receptors of the cerebral vessels. These receptors are located outside the cerebral blood brain barrier and can be considered as 'peripheral' ones.
PubMed: 1931472
Links to Exploration step
pubmed:1931472Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.</title><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name><affiliation><nlm:affiliation>Laboratoire d'Hémodynamique Cérébrale, INSERM U230, Faculté de Médecine, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Celsis, P" sort="Celsis, P" uniqKey="Celsis P" first="P" last="Celsis">P. Celsis</name></author><author><name sortKey="Houin, G" sort="Houin, G" uniqKey="Houin G" first="G" last="Houin">G. Houin</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author><author><name sortKey="Marc Vergnes, J P" sort="Marc Vergnes, J P" uniqKey="Marc Vergnes J" first="J P" last="Marc-Vergnes">J P Marc-Vergnes</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1991">1991</date><idno type="RBID">pubmed:1931472</idno><idno type="pmid">1931472</idno><idno type="wicri:Area/PubMed/Corpus">001787</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001787</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.</title><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name><affiliation><nlm:affiliation>Laboratoire d'Hémodynamique Cérébrale, INSERM U230, Faculté de Médecine, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Celsis, P" sort="Celsis, P" uniqKey="Celsis P" first="P" last="Celsis">P. Celsis</name></author><author><name sortKey="Houin, G" sort="Houin, G" uniqKey="Houin G" first="G" last="Houin">G. Houin</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author><author><name sortKey="Marc Vergnes, J P" sort="Marc Vergnes, J P" uniqKey="Marc Vergnes J" first="J P" last="Marc-Vergnes">J P Marc-Vergnes</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></analytic><series><title level="j">British journal of clinical pharmacology</title><idno type="ISSN">0306-5251</idno><imprint><date when="1991" type="published">1991</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Apomorphine (administration & dosage)</term><term>Apomorphine (pharmacology)</term><term>Blood Pressure (drug effects)</term><term>Cerebrovascular Circulation (drug effects)</term><term>Domperidone (pharmacology)</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (physiopathology)</term><term>Psychomotor Performance (drug effects)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Domperidone</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term><term>Cerebrovascular Circulation</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. We have measured regional cerebral blood flow (rCBF) and motor function before and after the subcutaneous (s.c.) injection of apomorphine in parkinsonian patients deprived of their usual treatment for at least 48 h. 2. Nineteen patients, pretreated with domperidone (20 mg three times daily for 48 h), received a mean dose of 5.8 mg s.c. apomorphine. All patients switched 'on'. The mean motor score was significantly improved (-65%, P less than 0.01) but no significant change in rCBF was observed. 3. Seven other patients, not pretreated with domperidone, received a lower dose (0.3 mg) of s.c. apomorphine. No change in motor score was observed while the mean rCBF significantly increased (+12%, P less than 0.05). 4. We conclude that s.c. apomorphine increases rCBF in parkinsonian patients. This effect is independent of the central therapeutic effects of the drug. It is mediated by the stimulation of dopaminergic receptors of the cerebral vessels. These receptors are located outside the cerebral blood brain barrier and can be considered as 'peripheral' ones.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1931472</PMID><DateCreated><Year>1991</Year><Month>12</Month><Day>26</Day></DateCreated><DateCompleted><Year>1991</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0306-5251</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.</ArticleTitle><Pagination><MedlinePgn>229-34</MedlinePgn></Pagination><Abstract><AbstractText>1. We have measured regional cerebral blood flow (rCBF) and motor function before and after the subcutaneous (s.c.) injection of apomorphine in parkinsonian patients deprived of their usual treatment for at least 48 h. 2. Nineteen patients, pretreated with domperidone (20 mg three times daily for 48 h), received a mean dose of 5.8 mg s.c. apomorphine. All patients switched 'on'. The mean motor score was significantly improved (-65%, P less than 0.01) but no significant change in rCBF was observed. 3. Seven other patients, not pretreated with domperidone, received a lower dose (0.3 mg) of s.c. apomorphine. No change in motor score was observed while the mean rCBF significantly increased (+12%, P less than 0.05). 4. We conclude that s.c. apomorphine increases rCBF in parkinsonian patients. This effect is independent of the central therapeutic effects of the drug. It is mediated by the stimulation of dopaminergic receptors of the cerebral vessels. These receptors are located outside the cerebral blood brain barrier and can be considered as 'peripheral' ones.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Laboratoire d'Hémodynamique Cérébrale, INSERM U230, Faculté de Médecine, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Celsis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Houin</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marc-Vergnes</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5587267Z69</RegistryNumber><NameOfSubstance UI="D004294">Domperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1985 Aug;35(8):1127-34</RefSource><PMID Version="1">3875059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1985 Apr;71(4):257-66</RefSource><PMID Version="1">3873779</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1301-4</RefSource><PMID Version="1">3025375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1986;9(6):566-9</RefSource><PMID Version="1">3802109</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Pharmacol. 1986 Nov 19;131(2-3):229-36</RefSource><PMID Version="1">3816953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1988 Feb 20;1(8582):403-6</RefSource><PMID Version="1">2893200</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Therapie. 1988 Mar-Apr;43(2):83-8</RefSource><PMID Version="1">3406932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1988;144(5):367-71</RefSource><PMID Version="1">3420354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1987;2(4):279-89</RefSource><PMID Version="1">3509776</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1989 Feb;12(1):14-22</RefSource><PMID Version="1">2713864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1989 Jul;52(7):917-8</RefSource><PMID Version="1">2769291</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1989 Aug;26(2):232-8</RefSource><PMID Version="1">2774511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96-101</RefSource><PMID Version="1">2313313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1990 Jul 7;336(8706):32-4</RefSource><PMID Version="1">1973218</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1987 Aug;84(16):5995-9</RefSource><PMID Version="1">3497401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Neurol Scand. 1974;50(1):3-10</RefSource><PMID Version="1">4839058</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 1976 Sep;58(1):121-6</RefSource><PMID Version="1">974370</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 1978 Jul;63(3):481-4</RefSource><PMID Version="1">667492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1979 Mar 17;1(8116):570-2</RefSource><PMID Version="1">85162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1979 May 5;1(8123):954-6</RefSource><PMID Version="1">87620</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comput Assist Tomogr. 1980 Dec;4(6):727-36</RefSource><PMID Version="1">6971299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comput Assist Tomogr. 1981 Oct;5(5):641-5</RefSource><PMID Version="1">6975286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Int Pharmacodyn Ther. 1981 Aug;252(2):196-209</RefSource><PMID Version="1">7305558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drugs. 1982 Nov;24(5):360-400</RefSource><PMID Version="1">6756878</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1983 Mar 7;262(2):259-65</RefSource><PMID Version="1">6404503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1984 Jun;107 ( Pt 2):487-506</RefSource><PMID Version="1">6722513</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):824-30</RefSource><PMID Version="1">6332176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1985 Mar;108 ( Pt 1):171-91</RefSource><PMID Version="1">3978397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 1985 Jun;85(2):403-10</RefSource><PMID Version="1">3896363</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004294" MajorTopicYN="N">Domperidone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1368448</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1931472</ArticleId><ArticleId IdType="pmc">PMC1368448</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001787 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001787 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:1931472
|texte= Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1931472" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |